AtriCure (ATRC) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- HSBC Downgrades IBM (IBM) to Reduce, 'Stretched Valuation'
AtriCure Reports Second Quarter 2016 Financial Results
August 4, 2016 4:01 PM EDTRevenue of $39.7 million up 21.8% as reported, 21.5% constant currency U.S. sales of $30.9 million up 19.9% International sales of $8.8 million up 28.7% as reported, 27.4% constant currency
MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2016 financial results.
We are pleased to report second quarter results which reflect many accomplishments we launched two new products, made progress with our clinical trials and made strides in... More
